Background
de novo genetic variation in 3 positive cases; 5 genetic variations in ANK2 detected in 4 cases; variations in KCNJ2 together with CASQ2 in 1 case; genetic variations in RYR2, including a de novo genetic variation and desmosomal proteins encoding genes including DSG2, DSP and JUP, detected in 3 of the cases. Larger gene panels or whole exome sequencing should be considered to identify novel genes associated to Brugada Syndrome. However, application of approaches such as whole exome sequencing would difficult the interpretation for clinical purposes due to the large amount of data generated. The identification of these genetic variants opens new perspectives on the implications of genetic background in the arrhythmogenic substrate for research purposes.
Introduction
In the last 20 years, the advent of advanced genetics has enabled rapid progress in the field of inherited arrhythmogenic diseases associated with sudden cardiac death (SCD). In addition, the genetic data have been rapidly translated into the clinical field, to be used in diagnostic, risk stratification, and therapeutic strategies. Although genetics has been advocated as a tool to be interpreted in the context of the clinical phenotype as a complementary test, in the field of arrhythmogenic diseases genetics is emerging as a diagnostic tool in itself, providing a clue to unexplained death. Herein, genetics is not a complement, but a substitute for the unsuccessful clinical and forensic investigation [1] . Thus, in recent years we have moved from the use of genetics to confirm a known disease, to the use of genetics to diagnose an unknown disease.
The recent developments in massively parallel sequencing (next-generation sequencing, NGS) have provided access to thorough genetic screening. This technology is rapidly transitioning to clinical practice, adding a new level of complexity to patient diagnosis and care. NGS allows a fast and cost-effective approach for the genetic screening of a large panel of genes, representing an ambitious strategy compared with Sanger sequencing. When combined with inquiry into large-scale international genetic databases, NGS allows the scientific community to acquire deeper spectra of the genetic variants contributing to specific phenotypes. However, its use in clinical diagnosis remains a challenge due to the large amount of genetic information that has to be interpreted to evaluate its pathological relevance.
NGS is beginning to be applied to arrhythmogenic diseases like Brugada syndrome (BrS). The BrS is a rare, inherited arrhythmogenic disorder characterized by the presence of ST-segment elevation in the right precordial leads (V 1 to V 3 ), referred to as electrocardiogram (ECG) type I. BrS causes SCD in the structurally normal heart, and affects predominantly men during the third and fourth decade of life. Although the disease has classically been described as a primary electrical disorder involving the sodium channel and leading to the characteristic ECG, it has been proposed that BrS may actually encompass a heterogeneous group of disorders with a variety of genetic and clinical phenotypes. Currently, the major genetic contribution to BrS is variation in the SCN5A gene, which represents 20_25% of all clinically diagnosed BrS cases.
Another 15 genes have been associated with the disease, but together represent only about 5_10% of BrS cases [2] . Thus, close to 70% of BrS cases remain unexplained after comprehensive genetic analysis of all previously associated genes. Current guidelines recommend to genetically screening restricted to the SCN5A gene as the most resolute and cost-effective strategy for genetic diagnosis of Brugada Syndrome affected patients [3] [4] To evaluate the role of genetic variants in arrhythmogenic diseases, we used NGS technology to resequence 28 main genes associated with arrhythmogenic SCD in a cohort of BrS patients. The results allow us to assess the value of this approach in confirming a diagnosis of a clear clinical phenotype and also to draw conclusions on its potential value in forensic investigation of patients with unexplained SCD.
Materials and Methods

Patient recruitment
We retrospectively recruited a total of 45 samples/clinical histories of adult patients clinically diagnosed with BrS in a multicenter effort. These samples serve as the index case in each family. All index cases included in the study were negative for pathogenic genetic variants in SCN5A (see below). Informed consent for all samples was obtained in accordance with local institutional review board guidelines of the Hospital Josep Trueta (Girona, Spain) and conforms to the principles outlined in the Declaration of Helsinki. The project was approved by the local review board (Hospital Josep Trueta-Girona). All patients and relatives signed their written consent for research purposes before participation in this study. The diagnosis of BrS was accepted when the patients showed an ECG type 1 (basally or after the administration of intravenous sodium channel blockers) in conjunction with at least one clinical criterion, reflecting the occurrence of documented ventricular arrhythmia, family history (of SCD or BrS), and/or symptoms secondary to arrhythmia. Structural heart disease was ruled out in all participating individuals. S2 Fig and S3 Fig show two examples of ECG type 1 observed in two of the cases included at the study.
Target enrichment: Custom resequencing panel
At the moment of the study, we had genetically analyzed a total of 63 individuals for SCN5A by conventional Sanger sequencing: 18 of them resulted genetically positive for SCN5A (29% of the cases) and the remaining 45 cases (71% of the cases) remained genetically negative. These percentages are in agreement with data described in the literature and guidelines. In all these 45 samples, neither pathogenic nor potentially pathogenic variations were detected after Sanger sequencing of SCN5A. All 45 BrS cases were genetically evaluated by means of target resequencing of exonic, UTR, and intron-exon boundary regions of 28 core genes related to SCD, included in a panel of massively parallel sequencing in SOLID 4 platform (Life Technologies Waltham, MA USA). This panel includes AKAP9, ANK2, CACNA1C, CACNB2, CASQ2,  CAV3, DSC2, DSG2, DSP, GPD1L, HCN4, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2,  KCNJ5, KCNQ1, NOS1AP, PKP2, RYR2, SCN1B, SCN3B, SCN4B, SCN5A, SNTA1 , and TMEM43. We included genes associated with cardiac channelopathies as well as genes associated with arrhythmogenic right ventricular cardiomyopathy (ARVC), a disease difficult to diagnose in its incipient forms even with powerful imaging techniques ( Table 1) .
The custom design of the Resequencing Panel is explained in S1 Methods. The 28 genes were enriched using SureSelect Custom Target Enrichment System kit (Agilent Technologies, Santa Clara_CA USA) following manufacturing protocol "SureSelect Target Enrichment System for SOLiD Fragment and Paired-End Sequencing version 1.3." (See S1 Methods for custom design of the resequencing panel and the bioinformatics pipeline explanation and S1 Fig for  sequencing statistics) The median percentage of reads on target was 46% for all 45 samples (ranging from 43% to 52%). The median coverage was 129x (ranging from 100x to 179x), and the 25th, 75th, and 95th percentiles were 83x, 216x, and 469x, respectively. (See S1, S2 and S3 Tables)
Variant validation and familial segregation study
Potential pathogenic rare variants with a MAF (minor allele frequency) under 1% were consulted in locus-specific databases that included dbSNP [5] , Ensembl genome browser [6] , the 1000 Genomes Project [7] , and EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project _ESP).
All genetic variants detected in the index cases were validated by conventional Sanger sequencing. Previously published function-affecting variants as well as potential pathogenic genetic variants were also analyzed in a total of 85 relatives by direct sequencing of those genomic positions. In silico analysis of pathogenicity of rare nonsynonymous variants was performed with Condel Analysis [8] Mutation Taster (http://www.mutationtaster.org/), Polyphen (http://genetics. bwh.harvard.edu/pph2/), and Provean (http://provean.jcvi.org/) ( Table 2 and S1 Methods). Data related to genetic variants detected in the study were submitted to the Leiden Open Variation Database 3.0 (URL http://www.lovd.nl/3.0/home) ( Table 2) . We have recently published a restrictive score to consider the potential pathogenicity of a genetic variant for clinical assessment [9] . This score was applied to the variants presented in this article ( 
Genetic results
Thirty genetic variants, all of them in exonic regions of 12 genes, were detected in the heterozygous state in 22 index cases ( 
Segregation studies
After segregation and bioinformatic analyses, several potentially pathogenic rare variants were identified in the 22 cases. These variants would be labeled as potentially causative in the event of a screening performed in the single individual, victim of a cardiac arrest, or as part of the forensic investigation of unexplained sudden death. Multiple genetic variants were detected in 6 cases ( Table 2) . Clinical data and family segregation are summarized in S4 Table. Family pedigrees are shown in Fig 1 to Fig 12. These figures show the phenotype of relatives as positive or negative for BrS diagnosis. Clinical information of relatives is essential information to ascertain the pathogenicity of the genetic variant that was detected in each index case after NGS. Taking these data into account, we proceeded to divide the groups into three main classes according to segregation variable: Table and Table 2 for segregation results, familial clinical history and rare variant report and classification). Incomplete penetrance pattern of the detected variants is also considered into this first group. This group includes 12 cases.
In the first 6 cases, the detected genetic variation showed complete penetrance. In cases 1 and 2 (Figs 1 and 2) the segregation variant was detected in the ANK2 gene. In case 3, two variations, in CASQ2 and KCNJ2, correlate with the disease in this large family with a history of SCD (Fig 3) . In case 4 the variant was detected in HCN4 (Fig 4) . In case 5, the variant was detected in JUP (Fig 5) . Case 6 showed a novel de novo variation in the RyR2 gene (Fig 6) . In these 6 cases, 6 additional potentially functional affecting variants were also identified. However, those 6 variations did not segregate with the pathology in the family. The remaining 6 cases in this first group showed an incomplete penetrance pattern of inheritance (Table 2 ). In two cases, 7 and 8 (Figs 7 and 8), the genetic variation was detected in AKAP9. Case 9 (Fig 9) had two genetic variants, in ANK2 and PKP2. The remaining three cases had variants in DSP and PKP2 (Fig 10 to Fig 12) .
Group 2. Unclear segregation (see Table 2 for rare variant report and classification). The second group includes those cases in which DNA was not available for genetic resequencing from relatives, therefore prohibiting ascertainment of segregation. This group comprises 5 cases (Table 2 ), in which 6 variations were detected in 6 different genes.
In case 13 the genetic variation detected in ANK2 c.5758G>A; (p.(Gly1920Arg)) was previously catalogued as rs140189724 and predicted as neutral. Family history included a brother affected with BrS. Case 14 was a carrier of a previously undescribed genetic variation in CAC-NA1C c.5875G>C; (p.(Gly1959Arg)), predicted as neutral. He was a 33-year-old man diagnosed after an aborted SCD event, with a positive ECG at baseline. His father experienced detected in case 17, a 46-year-old man with a positive ECG at baseline. Both were predicted as deleterious. Family history included two uncles who died suddenly. Group 3. Negative segregation (see Table 2 for rare variant report and classification). The third group includes 5 cases in which the variations detected did not segregate with the phenotype in the available family members (Table 2) ; these cases therefore remain undiagnosed genetically. Interestingly, the variants detected were predicted as pathogenic by informatics tools.
In case 18 the variation ANK2 c.2945G>A (p.(Arg982Gln)), not previously described, was identified and was predicted deleterious. Two of the case's four children were also diagnosed with BrS but did not carry the detected variant. Case 19 belonged to a large family with history of sudden death. In recent years, some compendiums focusing on the genetics of BrS have been published. These studies performed Sanger sequencing of known BrS-related genes and showed that 20 to 25% of BrS patients carry a pathogenic variation in the SCN5A gene. However, nearly 70% of BrS patients remain without genetic cause after genetic analysis. Accordingly, the Canadian Cardiovascular Society/Canadian Heart Rhythm Society expert consensus statement suggested genetic testing only of the SCN5A gene for any patient diagnosed with BrS. This consensus recommends that the genetic testing of minor BrS-associated genes should only be considered under special circumstances, given the difficulty of drawing clinical conclusions from few patients with these genetic defects and the low yield of genetic testing in these less prevalent genes [3] .
However, the development of high-throughput technologies allows the screening of large sets of genes at once. Therefore, NGS technology is progressively being incorporated into clinical diagnosis. To the best of our knowledge, our study is the first comprehensive genetic analysis using NGS technology to identify genetic variants associated with BrS. Indeed, in our study, NGS resequencing of individuals with BrS detected a total of 30 rare genetic missense variants in the heterozygous state; all were validated by conventional Sanger sequencing.
The study had three main purposes: 1. to determine genetic causality in patients with BrS who did not carry a variation in SCN5A; 2. to assess the value of NGS technology and bioinformatics tools in determining causality; and 3. to use these data to interpret genetic causality in the event that these were cases of unexplained SCD. These objectives are critical to determining whether there exists a role for NGS in the clinical diagnosis of sudden death, especially considering that the current recommended strategies to determine causality are not definitive: segregation analyses may not always be possible, bioinformatics pathogenicity prediction may not always be accurate, and functional analyses are never performed for clinical determination of causality. The lack of this in vitro/in vivo analysis is the main limitation to determining the score of pathogenicity. However, using NGS data, and accepting present limitations and present knowledge, we have identified several variants potentially causative of BrS, based on low prevalence in the general population. 
Next-Generation Sequencing in Brugada Syndrome
ANK2
Previous studies demonstrated the role of ankyrin, especially ankyrin-G, in the sodium channel trafficking that results in several life-threatening conditions including cardiac arrhythmias. While ankyrin-G is required for the targeting of Nav1.5 to the cardiomyocyte intercalated disc, ankyrin-B is required for targeting the Na + /Ca ++ exchanger and Na + /K + ATPase to transverse tubule membranes in the heart. Interestingly, ankyrin-B knockout mice exhibit a delayed opening of the sodium channel, although no evidence of an interaction between the sodium channel and ankyrin-B has been reported so far. ANK2 (encoding ankyrin-B) was previously associated with LQTS type 4, producing a loss-of-function effect. A total of 5 genetic variations in ANK2 were detected in 4 cases. Cases 1 and 2 had complete penetrance; in case 13 a segregation study could not be completed as DNA was not available from relatives; and in case 18 the variant did not segregate with the pathology in the family. The incidence of these rare variants implicates 
Next-Generation Sequencing in Brugada Syndrome
ANK2 as a potential candidate gene in BrS. Further functional and molecular studies of the detected variants should clarify the molecular mechanisms related to pathogenic variations in the ANK2 gene that underlies a BrS phenotype [13] [14] [15] . Next-Generation Sequencing in Brugada Syndrome
CASQ2
Homozygous variations in CASQ2 are associated with recessive forms of catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited arrhythmogenic disorder associated with SCD. However, CASQ2 was not previously associated with BrS. CASQ2 encodes calsequestrin, which is located inside the sarcoplasmic reticulum (SR) and buffers the physiological intra-SR calcium. In case 3, the genetic variant in CASQ2 was accompanied by a second variant, in KCNJ2, which also segregated with the pathology. Variations in KCNJ2 are associated with LQTS type 7 and short QT syndrome. A related gene, KCNJ8, has been associated with BrS, though at present it appears that some of the variations are actually normal variants in the general population. In addition, in this family, two members carry both genetic variations are also clinically diagnosed for AF. This fact agrees with the pathogenic variations reported in the KCNJ2 gene in patients diagnosed with AF [16] , [17] .
HCN4
HCN4 encodes the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 and was previously associated with BrS. In the Human Gene Variation Database (HGMD), 10 variations in HCN4 have been described, with just one of them associated with BrS [18] . The variant we detected was previously reported but not classified for its pathogenic effect. In silico database analysis predicted the variation rs200507617 as deleterious.
Desmosomal proteins
Although, historically, genes encoding desmosomal proteins have not been associated with BrS, Cerrone et al. recently defined the co-existence of clinical BrS and genetic variations in PKP2, which encodes the desmosomal protein plakophilin [10] . Desmosomal proteins, particularly plakophilin and desmoglein, interact with Nav1.5, [19] . Indeed, a recent review proposed that alterations in the "connexome" are the origin of BrS [20] . This interaction could be a possible explanation of the observed variation in genes encoding desmosomal proteins in BrS in our study. We identified several variations in JUP, DSP, PKP2, and DSG2. Variants of these desmosomal proteins are associated with ARVC and dilated cardiomyopathy (DCM), both structural heart pathologies associated with SCD. In case 5 we detected the variant JUP p. Val159Leu, previously associated with ARVC (CM1010258) [21] . Cases 21 and 22 carried a genetic variant in DSG2. Although these did not segregate with the pathology, one of the variations, rs191143292, was already published as pathogenic and causal for ARVC [22] . These genetic variations detected in our cohort should be further studied to clarify their role in BrS. doi:10.1371/journal.pone.0133037.g012
Next-Generation Sequencing in Brugada Syndrome
RYR2
Genetic variants in the RyR2 gene were also detected in our cohort. RyR2 encodes the ryanodine receptor 2. Variations in this gene have been associated with CPVT and LQTS. Arrhythmia susceptibility in LQTS individuals may be due to two distinct Ca 2+ mechanisms: the early afterdepolarizations (EADs), which are driven by reactivation of the L-type calcium channels during repolarization, and a mechanism that may occur during diastole (delayed afterdepolarizations, DAD) via Ca 2+ cycling by altering the function of the cardiac RyR2 channel [23] . The detected variation segregates in case 6, but in case 17 segregation could not be established. To date, no association between BrS and this gene has been described, though calcium channels have been associated with the disease [24] .
Calcium channels
Several genetic variations in two calcium channel genes were identified in our samples. Two variants were detected in CACNA1C, which encodes Cav 1.2. However, segregation analysis was not available in case 14, and no segregation was shown in case 19. Similarly, the segregation study was negative in case 20 for the genetic variant in CACNB2. Although both genes have been associated with BrS [24] , analysis of variants did not clarify their pathogenic role in BrS. Although calcium channels and their associated proteins have been proposed as candidates for BrS pathogenesis, we cannot make any conclusion for their role following NGS and segregation analysis of the detected variants.
AKAP9
Two cases showed genetic variations in AKAP9, both with incomplete penetrance. AKAP9 encodes Yotiao protein, associated with LQTS and having a critical contribution to I ks regulation [25] . As other potassium channels, such Kv4.3, MiRP1, and MiRP2, have been associated with BrS, similar mechanisms could underlie BrS in these cases.
De novo variants in RyR2 and AKAP9
Two de novo variations were identified; one in case 6, RyR2 p.I1268T/c.3803T>C, and one in case 7, AKAP9 (p.(Tyr2858Cys)). The latter was detected together with AKAP9 (p.(Arg 1276Gln)). However, in case 7 this novel variation did not correlate with the pathology, as the affected individual II.3 (Fig 8) did not carry the variation. Only 3 of the 12 genes in which we have identified potentially pathogenic variations were previously associated with BrS-four, considering the recently published data in PKP2 [10] . All these genes are likely new candidate genes as all are already associated to arrhythmogenesis and SCD. In addition, the in silico predictor tools together with the genetic variation frequency in general population and, most importantly the segregation analysis in relatives make all these genes, make these genes good candidate genes to further investigate their role in the genetic substrate of BrS. These results need to be further evaluated in larger BrS cohorts to investigate their function in BrS pathogenesis. The identified variants should be examined in cellular models to further confirm causality. The studies could provide novel mechanistic insights into BrS and arrhythmogenesis.
With these data, we show that several other genes may potentially be causative of the disease, genes that had been previously associated with other arrhythmogenic diseases. As is well known in these other arrhythmogenic diseases, most of the detected variants showed incomplete penetrance. The lack of phenotype in carriers does not preclude segregation, as there can be latent phenotypes, differences in gender and age, or the presence of genetic modulators. In addition, several variants may be identified in these cases. The possible combination of multiple variants could have an essential role in the variability in phenotype expression. Several modifying genetic factors have been described in BrS, and some additional ones have been proposed [26] [27]. Bezzina et al. described genetic variants that show a cumulative large effect on BrS susceptibility [28] . As in other SCD-related syndromes, like LQTS, variation in the expressivity related to several genetic variations has been described [29] [30] .
Segregation, or lack thereof, was believed to provide a definite lack of association with causality. However, in recent years some data have questioned this for BrS. In some of the families, clinically affected family members do not share the variation in SCN5A. Lack of segregation may indicate either that this is not a causative variation or that it is a predisposing genetic factor, albeit weaker than once thought. Previous data show the lack of complete segregation of SCN5A variations in some families [31] , as well as the presence of induced ST elevation as the first ECG alteration just before the SCD event [32] . This raises the hypothesis that the BrS ECG could actually be an electrical pattern triggered by a genetic predisposition to electrical instability, but which goes beyond pure Mendelian genetics. It is in this context that the data presented here can be scientifically understood. It is unlikely that there is an additional presence of variations associated with other diseases in patients with BrS, given that these are such rare diseases. The ECG pattern could be the result of combining either a strong genetic background (variation in SCN5A), or several minimal genetic alterations, with a certain structural makeup of the right ventricle that predisposes to slowing of conduction.
Several new bioinformatics tools enable an approach to the level of pathogenicity, which assesses, among other factors, the absence of the variation in the normal population as well as the effect of the variation in the protein. The localization of a rare missense variant in a critical area of the cardiac ion channel protein, or a truncating variation in major associated genes, are supposed to be pathogenic [33] . In silico prediction tools are thought to be useful when they show a deleterious score, but its value in neutral and benign scores seems less robust. In cases included in group 3, Segregation analyses definitively indicated that the variants were not causative, but it remains to be seen if, in the future, they will be classified as genetic modulators of the phenotype.
New minority genes had been recently associated with BrS (SCN2B, SCN10A, RANGRF, SLMAP, ABCC9, KCNJ8, KCND3, KCNE5, CACNA2D1 and TRPM4). These genes were not included when the resequencing panel was designed. Although the percentage of genetically positive cases in those genes is low, these genes should be considered when re-designing resequencing panel for genetic screening of BrS to get more data in several cohorts that support the association of these genes with the disease. Of note, current recommendations on general guidelines are still restricted to SCN5A. We can therefore hypothesize that in the clinical arena whole exome sequencing in BrS patients could result even in more harm at the moment due to the large amount of data generated and needed to be interpreted. However, in large well-characterized families, the whole exome sequencing should be considered for research purposes.
An exhaustive bioinformatic analysis did not detect insertions/deletions or copy number variations in our samples. This analysis was developed by using an in-house bioinformatics pipeline (manuscript under construction).
Conclusions
In conclusion, this work highlights the challenges that we face in the diagnosis of unexplained SCD. We have used BrS as a paradigm of unexplained sudden death in the structurally normal heart. We show that the identification of a genetic defect in the victim is not equivalent to providing a clear diagnosis. The identified genetic defects have provided a potential diagnosis of BrS, LQTS, CPVT, and ARVC. Massively parallel sequencing confirms that it is not always possible to determine the phenotype from genetic data. The inclusion of functional analyses could be determinant to assign a definite diagnosis, but this is not possible at the present rate of variation detection. Therefore, the introduction of NGS technology has led to more questions unanswered compared with the pre-NGS era. This was an expected challenge that always comes about in these approaches when large lists of genes are interrogated. The sequencing process of those genes gives huge amounts of data that had to be stored, analyzed and biologically and clinically interpreted. Genetic diagnosis by means of NGS is still a challenge since its application to clinical diagnosis requires first an international effort for better understanding of the significance of the rare genetic variations detected. One of the main objectives of the present work is to evaluate the applicability of NGS to clinical (and forensic) diagnosis. After the analysis of our results, this objective appears difficult to assess and only possible from a familiar perspective. However, even with the availability of relatives to enlarge the segregation study, the genetic diagnosis is still difficult to estimate. Detection of novel, presumed disease causing, rare genetic variants in several genes that were not previously associated to BrS are logical consequence of the study. Association of those genes to the disease need to be further evaluated by means of functional studies and replicated in different cohorts before being considered as genetically conclusive for clinical diagnosis. Several reason support that the genes described above should be considered candidate genes for research purposes for better understanding of genetics mechanisms underlying. These reason iclude the role of the proteins encoded by these genes, the low frequency or their absence of the genetic variations in general populations, their potential pathogenicity evaluated in silico and when possible, with the segregation analysis performed. These facts suggest a pathogenic role of the genetic variation detected. However, they are considered as VUS after applying the algorithm, mainly due to the lack of functional studies and genotype-phenotype analysis in different familiar cohorts. It is common that rare variants remains as VUS. This observation agrees with the characteristic of pathologies with incomplete penetrance and variable expressivity observed. To ascertain the pathogenic role of the detected variations, genotype-phenotype correlations are required in other familiar cohorts as part of international efforts to further increase understanding of the mutation spectrum underlying BrS. In this direction, GWAS analysis (ya existen) from international consortiums including several BrS cohorts had been published and also are nowadays being developed. These results would result clarifying and open new research perspectives to be evaluated, Technological progress has been more rapid than our capacity to apply it in the clinical arena. The genetic architecture in terms of genes involved, rare and common genetic variants, and modifying factors creates a complex decision network that can only be unraveled by careful clinical and genetic interpretation in a family context. This reinforces the need for accurate and thorough familial investigation, but also the importance of having the data handled by experts in the field, so as to understand the value but also the limitations of these NGS tests. 
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